Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01014130 | Hypofractionated Radiotherapy (Stereotactic) Versus Conventional Radiotherapy for Inoperable Early Stage I Non-small Cell Lung Cancer (NSCLC)(CHISEL) | unknown | Phase 3 | 101 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Jul 12, 2017 | clinicaltrials |
| NCT03205930 | Neo-MASCT Immunotherapy for Advanced NSCLC. | unknown | Phase 1 / Phase 2 | 20 | The First People's Hospital of LianyungangOTHER | 1 | Jul 5, 2017 |
| clinicaltrials |
| NCT03195569 | To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer | unknown | — | 15 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 22, 2017 | clinicaltrials |
| NCT02896166 | Microwave Ablation in the Treatment of Stage I Non Small Cell Lung Cancer | unknown | Phase 3 | 150 | Shandong Provincial HospitalOTHER_GOV | 1 | Jun 14, 2017 | clinicaltrials |
| NCT02381808 | Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China | unknown | — | 150 | Guangdong Association of Clinical TrialsOTHER | 1 | Jun 7, 2017 | clinicaltrials |
| NCT03154242 | Effect of Genetic Polymorphisms on Platinum Based Chemotherapy in Non Small Cell Lung Cancer | unknown | — | 60 | Ain Shams UniversityOTHER | 1 | May 16, 2017 | clinicaltrials |
| NCT01963195 | Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy | unknown | Phase 2 | 30 | Anhui Medical UniversityOTHER | 1 | May 8, 2017 | clinicaltrials |
| NCT03123445 | Endostar First-line Treatment of Advanced NSCLC | unknown | Phase 2 | 150 | China Medical University, ChinaOTHER | 0 | Apr 21, 2017 | clinicaltrials |
| NCT03123484 | β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC | unknown | Phase 2 | 80 | China Medical University, ChinaOTHER | 0 | Apr 21, 2017 | clinicaltrials |
| NCT02577627 | Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC | unknown | — | 5,000 | Optimata Ltd.INDUSTRY | 1 | Apr 4, 2017 | clinicaltrials |
| NCT02844114 | Clinical Study of Ganoderma Lucidum Spore Combined With Chemotherapy(LCKY2015-21(x)) | unknown | Phase 2 | 60 | Gao YajieOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT03090815 | Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma | unknown | — | 100 | The University of Hong KongOTHER | 1 | Mar 27, 2017 | clinicaltrials |
| NCT02714608 | A Study of Ginsenoside H Dripping Pills for Advanced Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 144 | Tasly Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 21, 2017 | clinicaltrials |
| NCT02951611 | Effects of Acupuncture Stimulation on Systemic Inflammation | unknown | N/A | 60 | RenJi HospitalOTHER | 1 | Mar 17, 2017 | clinicaltrials |
| NCT03078959 | Prognostic Value of PD-L1 in NSCLC | unknown | — | 350 | Fondazione Ricerca TraslazionaleOTHER | 0 | Mar 14, 2017 | clinicaltrials |
| NCT02695550 | Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer | unknown | Phase 1 | 40 | Centaurus Biopharma Co., Ltd.INDUSTRY | 1 | Mar 9, 2017 | clinicaltrials |
| NCT03074864 | Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC(TREND) | unknown | Phase 2 / Phase 3 | 90 | Guangdong Provincial People's HospitalOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT02055144 | Veristrat as Predictor of Benefit of First Line Non Small Cell Lung Cancer (NSCLC) Patients From Standard Chemotherapy | unknown | — | 100 | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, ItalyOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT03071705 | Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma | unknown | N/A | 120 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT01980472 | Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients | unknown | Phase 2 | 50 | Grupo de Investigación y Divulgación OncológicaOTHER | 1 | Feb 27, 2017 | clinicaltrials |
| NCT02282267 | Blood Detection of EGFR Mutation For Iressa Treatment(Benefit) | unknown | N/A | 188 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 24, 2017 | clinicaltrials |
| NCT02332512 | Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)(ANSWER) | unknown | Phase 3 | 417 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 24, 2017 | clinicaltrials |
| NCT03060343 | Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC) | unknown | Early Phase 1 | 10 | Yu FengleiOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT03057340 | The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting Activation of Tcells | unknown | Phase 1 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Feb 20, 2017 | clinicaltrials |
| NCT02974933 | Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer | unknown | Phase 2 | 48 | Wuling OuOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT03053804 | Clinical Application of MR-PET in Non-small Cell Lung Cancer: Diagnosis, Treatment Outcome, and Prognosis Prediction | unknown | N/A | 75 | National Taiwan University HospitalOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT03053856 | Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients | unknown | Phase 2 | 37 | Samsung Medical CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT03050411 | Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer | unknown | Phase 1 | 30 | Peking University Third HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT03050437 | A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI | unknown | Phase 2 | 96 | Samsung Medical CenterOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT01714908 | Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21(RECEL) | unknown | Phase 2 | 100 | Jinming YuOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT01744925 | Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT02370017 | Combined Effect of Natural Killer Cell and Doublet Chemotherapy in Advanced NSCLC as the 1st Line Treatment(ANKL-2) | unknown | Phase 2 | 68 | The Catholic University of KoreaOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT02568033 | Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer | unknown | Early Phase 1 | 22 | The Cooper Health SystemOTHER | 1 | Jan 31, 2017 | clinicaltrials |
| NCT02988141 | EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC(PRECENT) | unknown | — | 100 | Jianxing HeOTHER | 0 | Jan 20, 2017 | clinicaltrials |
| NCT02851329 | Therapeutic Resistance Prediction of Tyrosine Kinase Inhibitors | unknown | — | 500 | Chinese Academy of SciencesOTHER_GOV | 1 | Jan 19, 2017 | clinicaltrials |
| NCT01885754 | Characterization of Peripheral Muscle Function in Patients With Non-small-cell Lung Cancer | unknown | — | 56 | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de QuebecOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT03002844 | EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism | unknown | Phase 2 | 50 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Dec 28, 2016 | clinicaltrials |
| NCT02997449 | Complete Endosonographic Intrathoracic Nodal Staging of Lung Cancer Patients in Whom SABR is Considered | unknown | — | 102 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 2 | Dec 20, 2016 | clinicaltrials |
| NCT02029209 | To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer | unknown | Phase 2 / Phase 3 | 110 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 16, 2016 | clinicaltrials |
| NCT02839954 | CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02587689 | Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT02975609 | Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer | unknown | Phase 2 | 100 | Shanghai Chest HospitalOTHER | 1 | Nov 29, 2016 | clinicaltrials |
| NCT02758314 | Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients | unknown | — | 150 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT02787447 | Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy | unknown | Phase 2 | 46 | First People's Hospital of HangzhouOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT02787473 | A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer | unknown | Phase 2 | 54 | First People's Hospital of HangzhouOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT02274337 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT02972333 | Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M | unknown | Phase 3 | 150 | Shandong Cancer Hospital and InstituteOTHER | 0 | Nov 23, 2016 | clinicaltrials |
| NCT02755675 | uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung | unknown | Phase 2 | 120 | Rigshospitalet, DenmarkOTHER | 1 | Nov 21, 2016 | clinicaltrials |
| NCT02960607 | High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC | unknown | Phase 2 | 25 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT02961270 | Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 11, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jul 12, 2017source: clinicaltrials